高级检索
当前位置: 首页 > 详情页

IL-32 gamma promotes integrin alpha v beta 6 expression through the activation of NF-kappa B in HSCs

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Clinical Laboratory, The Third Affiliated Hospital, Sun Yat‑Sen University,Guangzhou, Guangdong 510630 [2]Department of Clinical Laboratory, The Second Affiliated Hospital,Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120 [3]Department ofInfectious Diseases, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou,Guangdong 510150 [4]Department of Infectious Diseases,The Third Affiliated Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China [5]Vaccine Research Institute,The Third Affiliated Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China
出处:
ISSN:

关键词: interleukin-32 gamma hepatic stellate cells integrin alpha v beta 6 hepatic fibrosis

摘要:
Hepatic stellate cell (HSC) activation is important in the pathogenesis of liver fibrosis. However, the molecular mechanism of HSC activation is not completely understood. In the present study, it was demonstrated that interleukin-32 gamma (IL-32 gamma) is capable of enhancing intefgrin alpha v beta 6 expression by inducing integrin alpha v beta 6 promoter activity in a dose-dependent manner in HSCs. Furthermore, it was determined that nuclear factor kappa B (NF-kappa B)activation is required for IL-32 gamma-induced integrin alpha v beta 6 expression. Increased integrin alpha v beta 6 expression is then able to activate HSCs. These results indicate that NF-kappa B activation is required for IL-32 gamma to induce integrin alpha v beta 6 expression and consequently promote HSC activation. Therefore, IL-32 gamma activates HSCs and therefore may be associated with hepatic fibrogenesis. These results may enable the development of novel effective strategies to treat hepatic fibrosis.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2015]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Department of Clinical Laboratory, The Third Affiliated Hospital, Sun Yat‑Sen University,Guangzhou, Guangdong 510630 [2]Department of Clinical Laboratory, The Second Affiliated Hospital,Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120
共同第一作者:
通讯作者:
通讯机构: [4]Department of Infectious Diseases,The Third Affiliated Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China [5]Vaccine Research Institute,The Third Affiliated Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China [*1]Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat‑Sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, P.R. China [*2]Vaccine Research Institute, The Third Affiliated Hospital, Sun Yat‑Sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号